Table 4.
Comparison Of Microbiological Characteristics In Patients With Mono-EBSI Or Mixed-EBSI
| Total (n=451) | Mono-EBSI (n =294) | Mixed-EBSI (n =157) | P-value | |
|---|---|---|---|---|
| Source of BSIs | ||||
| Intra-abdominal | 155(34.4%) | 114(38.8%) | 41(26.1%) | 0.007 |
| Primary BSI | 130(28.8%) | 84(28.6%) | 46(29.3%) | 0.871 |
| Pneumonia | 62(13.7%) | 41(13.9%) | 21(13.4%) | 0.867 |
| Skin and Soft tissue infection | 43(9.5%) | 17(5.8%) | 26(16.6%) | <0.001 |
| Central venous catheter | 38(8.4%) | 18(6.1%) | 20(12.7%) | 0.016 |
| Urinary tract infection | 12(2.7%) | 9(3.1%) | 3(1.9%) | 0.470 |
| Intracranial | 5(1.1%) | 5(1.7%) | 0(0.0%) | 0.168 |
| Endocarditis | 4(0.9%) | 4(1.4%) | 0(0.0%) | 0.303 |
| Othersa | 2(0.4%) | 2(0.7%) | 0(0.0%) | 0.545 |
| Antibiotic resistance of Enterococcusb | ||||
| Ampicillin (285 vs. 154)c | 229(52.2%) | 163(57.3%) | 66(42.9%) | 0.004 |
| Ciprofloxacin (294 vs. 157)c | 255(56.5%) | 172(58.5%) | 83(52.9%) | 0.250 |
| Tetracycline (208 vs. 112)c | 156(48.8%) | 93(44.7%) | 63(56.2%) | 0.049 |
| Erythromycin (236 vs. 113)c | 249(71.3.0%) | 172(72.9%) | 77(68.1%) | 0.359 |
| Levofloxacin (235 vs. 121)c | 210(59.0%) | 148(63.0%) | 62(51.2%) | 0.033 |
| Nitrofurantoin (239 vs. 132)c | 115(31.8%) | 84(35.1%) | 31(25.2%) | 0.054 |
| Teicoplanin (57 vs. 43)c | 1(1.0%) | 1(1.8%) | 0(0.0%) | 1 |
| Linezolid (288 vs. 152)c | 71(16.1%) | 41(14.2%) | 30(19.7%) | 0.136 |
| Vancomycin (294 vs. 157)c | 10(2.2%) | 8(2.7%) | 2(1.3%) | 0.505 |
| Treatment after the onset of BSIs | ||||
| Delayed antibiotic therapy | 74(16.4%) | 45(15.3%) | 29(18.5%) | 0.387 |
Notes: Bold indicates P<0.05; aSubmandibular gland, joint; bNot all agents listed tested in all isolates; cthe numbers in parentheses represent the total numbers of Enterococcus performed susceptibility test.
Abbreviation: EBSI, enterococcal bloodstream infections.